Can Dividend Stocks Novo Nordisk and Novartis Continue to Perform?

Novo Nordisk and Novartis have had a great start to their 2014, with shares climbing around 25% and 16%, respectively. And both pay a dividend -- Novo's is around 1.8%, while Novartis' is 3%, according to S&P Capital IQ. So they've had a great year so far, and income investors should keep an eye on them. But can they continue to outperform? Both stocks have opportunities to expand and threats from competitors coming online with new drugs.

In the video below, Motley Fool health care analysts Michael Douglass and David Williamson give their take on the two stocks and what they see as the opportunities and threats for each.

Even better dividend stocks?
The smartest investors know that dividend stocks simply crush their non-dividend paying counterparts over the long term. That's beyond dispute. They also know that a well-constructed dividend portfolio creates wealth steadily, while still allowing you to sleep like a baby. Knowing how valuable such a portfolio might be, our top analysts put together a report on a group of high-yielding stocks that should be in any income investor's portfolio. To see our free report on these stocks, just click here now.

The article Can Dividend Stocks Novo Nordisk and Novartis Continue to Perform? originally appeared on

David Williamson owns shares of Novartis. Michael Douglass has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2014 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story